• MOMA staff 2022

    MOMA staff 2022

  • MOMA entrance 2022
  • building

    Modern and spacious laboratories

  • NovaSeq

    Genetic Diagnostics by NGS

  • samples

    Traceability is part of quality assurance

  • Hamilton

    Automatisation by robots

  • diagnostics

    DNA Diagnostics

  • Blood Samples

    Processing of blood samples

  • NGS Core Center

    NGS Core Center since 2012

  • NGS Core Center 2022

    NGS Core Center - Send your request!

  • ctDNA

    ctDNA analysis

  • bioinf

    Bioinformatic data analysis

  • cellline

    Cell cultures

  • fluomic

    Fluorescence microscopy

  • ihc
  • ihc slice


  • cancer cells

    Colon adenocarcinoma cells

About MOMA

The Department of Molecular Medicine (MOMA) is part of Aarhus University Hospital, and is associated with the Institute for Clinical Medicine at Aarhus University.

MOMA was established in 2008 at the Science Center Skejby, nearby the hospital and reemerged as independent hospital department  from January, 1st 2020.

MOMA houses the National Whole Genome Sequencing Center West under the Danish National Genome Center, which will contribute to the development of precision medicine to the benefit of patients by sequencing ~60.000 genomes from 2019.

Read more about the department at moma.auh.dk (Danish) or at en.auh.dk (English).

Our main activities

Molecular diagnostic service for national and international hospitals

Molecular clinical research, mainly in cancer

National WGS Center West under the Danish National Genome Center

MOMA is accredited by DANAK/ILAC by the international laboratory standard DS/EN ISO 15189:2013 for medical examination - genetics since 2012.

Our comitted staff is counting more than 150 members, including six professors, consultants, doctors, molecular biologists, researchers, bioinformaticians, medical technologists and students.
MOMA collaborates with leading laboratories worldwide, especially in clinical translational studies. 

MOMA houses a wide range of state-of-the-art laboratory equipment.

We receive substantial research fundings from more than 50 funds including The Danish Cancer Society, The Innovation Fund Denmark , The Lundbeck FoundationThe Independent Research Fund Danmark, Novo Nordisk Foundation, Neye Foundation and many others. 



NGS Core Center Cell free DNA Analyses Genetic Analyses NormFinder software MethCORR software



Current Research Networks and Large Projects

Effects of Germline Structural Variation on the Biology and Pathology of the Large Intestine (2021-2024)

CIRCPAC – A National Randomized Trial Investigating the Clinical Benefit of circulating tumor DNA Guided Recurrence Surveillance After Resection for Pancreatic Cancer (2020-)

UTILITY - Using liquid tumor biopsies & genetic testing to guide personalized treatment of advanced prostate cancer: From discovery to clinical care. (2020-)

TOMBOLA - Treatment of Metastatic Bladder cancer at the time of biochemical reLApse following radicial cystectomy (2020-)

DCCC ctDNA Research Center - Danish National Center for Circulating Tumor DNA Guided cancer Treatment (2020-)

DCCC Danish circulating tumor DNA network (DCCC ctDNA) (2019-)

NorDCaP  - Nordic Implementation of Personalised Prostate Cancer Diagnostics (2019-)

PRIMA - Early and accurate detection of prostate cancer in general practice (2018-)

IMPROVE - Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer (2018-2025)

IMPROVE-IT - Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer (2018-2025)

IMPROVE-IT2 - Implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer – intervention trial 2 (2018-2025)

"Individualized monitoring of cancer by deep sequencing of circulating tumor DNA in patients with advanced bladder cancer "(2017-)

PROCARIS - A new strategy to prevent overdiagnosis and overtreatment of non-aggressive prostate cancer in the aging male population (2016-)

PAGER - Analyzis of personal genomic rearrangements for surveillance of patients with bladder cancer (2013-)

OPRA - Oncology Precision Medicine Project Aarhus (2017-)

NEXT - Danish study of personalised cancer therapy based on tumor genetics (2017-)

""Early detection of recurrence and more curative therapy for colon cancer patients" (2016-2020)

PanCancer Analysis of Whole Genomes (PCAWG) Project (2015-)


Research Groups at MOMA

Bladder Cancer Group (Lars Dyrskjøt)

Colon Cancer Group (Claus Lindbjerg)

Prostate Cancer Group (Karina Dalsgaard Sørensen)

Medical Research Group (Claus Gravholt)

Bioinformatics Groups: